Accordingly, the combination of ACT and DC-activating treatments such as TLR or STING agonists, as well as CD40 stimulation and vaccination with viral or tumor antigens, has been found to have implications for the in vivo expansion, persistence and polyfunctionality of infused T cells. The gene discussed is CD40; the disease is neoplasm.